Just published: our paper on cases of thrombosis with concurrent thrombocytopenia following AstraZeneca Covid-19 vaccine.

In March 2021, rare signals of unusual clotting with concurrent low platelets began to emerge in people who had received at least one dose of the AstraZeneca Covid-19 vaccine. In order to gain a better understanding of this association, we conducted a review of the spontaneous reports received by the Yellow Card scheme in the UK.
We examined the clinical and demographic characteristics of the people affected by this ‘thrombosis with thrombocytopenia syndrome’ (TTS), including outcomes of the TTS event. During the period May 2021- May 2022, 443 cases of TTS were reported to the Yellow Card scheme and of these, 81 (18%) were fatal. We found no statistical differences in fatality based on age or sex. Reports of TTS following the AstraZeneca Covid-19 vaccine to the Yellow Card scheme are highest following a first vaccine dose.
The benefits of vaccination with the AstraZeneca vaccine and other Covid-19 vaccines available in the UK continue to outweigh the risks.

For full details of our review, read the paper here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362462/pdf/40264_2022_Article_1217.pdf

Lane S, Shakir S. Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data. Drug Saf. 2022 Sep;45(9):1003-1008. doi: 10.1007/s40264-022-01217-9. Epub 2022 Aug 4. Erratum in: Drug Saf. 2022 Sep 3;: PMID: 35927605; PMCID: PMC9362462.